Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.
You can purchase shares of Cellectis (NASDAQ:CLLS) through any online brokerage.
Other companies in Cellectis’s space includes: Molecular Partners (NASDAQ:MOLN), Cabaletta Bio (NASDAQ:CABA), Galectin Therapeutics (NASDAQ:GALT), Atossa Therapeutics (NASDAQ:ATOS) and Adaptimmune Therapeutics (NASDAQ:ADAP).
Cellectis has a consensus price target of $9.17.
The stock price for Cellectis (NASDAQ: CLLS) is $1.9 last updated November 14, 2024 at 6:53 AM EST.
There are no upcoming dividends for Cellectis.
Cellectis’s Q3 earnings are confirmed for Monday, November 4, 2024.
There is no upcoming split for Cellectis.
Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.